BTK inhibitor–tolerant persister cells in MCL lead to resistance. Wang et al showed that MCL cells exposed to BTK inhibitors become giant persister cells that proliferate and gain resistance to therapies when the BTK inhibitors are stopped. The giant-cell state is controlled by a metabolic switch and could offer an opportunity to intervene in MCL therapeutic resistance. Professional illustration by Somersault18:24.